Impressive responses to ICB have been reported in a subset of AS patients (2, 19–28), with potential predictive markers including CD8+ lymphocytes expressing programmed cell death protein 1 (PD-1) and high tumor mutation burden (TMB) (29, 30). This evidence concerns the gene PDCD1 and neoplasm.